Tissue | Expression Dynamics | Abbreviation |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/YES1_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/YES1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/YES1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/YES1_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/YES1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/YES1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/YES1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/YES1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:007155915 | Prostate | Tumor | response to transforming growth factor beta | 76/3246 | 256/18723 | 6.86e-07 | 1.40e-05 | 76 |
GO:007156015 | Prostate | Tumor | cellular response to transforming growth factor beta stimulus | 72/3246 | 250/18723 | 4.47e-06 | 7.02e-05 | 72 |
GO:002240717 | Prostate | Tumor | regulation of cell-cell adhesion | 112/3246 | 448/18723 | 2.20e-05 | 2.80e-04 | 112 |
GO:004211015 | Prostate | Tumor | T cell activation | 117/3246 | 487/18723 | 9.22e-05 | 9.05e-04 | 117 |
GO:000715915 | Prostate | Tumor | leukocyte cell-cell adhesion | 89/3246 | 371/18723 | 6.33e-04 | 4.52e-03 | 89 |
GO:000268314 | Prostate | Tumor | negative regulation of immune system process | 101/3246 | 434/18723 | 8.70e-04 | 5.85e-03 | 101 |
GO:190303714 | Prostate | Tumor | regulation of leukocyte cell-cell adhesion | 81/3246 | 336/18723 | 9.26e-04 | 6.10e-03 | 81 |
GO:002240916 | Prostate | Tumor | positive regulation of cell-cell adhesion | 70/3246 | 284/18723 | 1.06e-03 | 6.87e-03 | 70 |
GO:005086314 | Prostate | Tumor | regulation of T cell activation | 78/3246 | 329/18723 | 1.86e-03 | 1.09e-02 | 78 |
GO:0043114 | Prostate | Tumor | regulation of vascular permeability | 16/3246 | 47/18723 | 4.27e-03 | 2.13e-02 | 16 |
GO:190303914 | Prostate | Tumor | positive regulation of leukocyte cell-cell adhesion | 57/3246 | 239/18723 | 6.17e-03 | 2.86e-02 | 57 |
GO:004677712 | Prostate | Tumor | protein autophosphorylation | 54/3246 | 227/18723 | 7.93e-03 | 3.52e-02 | 54 |
GO:00030183 | Prostate | Tumor | vascular process in circulatory system | 61/3246 | 263/18723 | 8.88e-03 | 3.84e-02 | 61 |
GO:004578528 | Skin | AK | positive regulation of cell adhesion | 85/1910 | 437/18723 | 3.40e-09 | 2.79e-07 | 85 |
GO:004211019 | Skin | AK | T cell activation | 85/1910 | 487/18723 | 5.16e-07 | 1.85e-05 | 85 |
GO:002240725 | Skin | AK | regulation of cell-cell adhesion | 79/1910 | 448/18723 | 8.55e-07 | 2.81e-05 | 79 |
GO:007155910 | Skin | AK | response to transforming growth factor beta | 52/1910 | 256/18723 | 9.55e-07 | 3.09e-05 | 52 |
GO:007156010 | Skin | AK | cellular response to transforming growth factor beta stimulus | 50/1910 | 250/18723 | 2.45e-06 | 6.76e-05 | 50 |
GO:005086317 | Skin | AK | regulation of T cell activation | 59/1910 | 329/18723 | 1.20e-05 | 2.46e-04 | 59 |
GO:000715919 | Skin | AK | leukocyte cell-cell adhesion | 64/1910 | 371/18723 | 1.87e-05 | 3.52e-04 | 64 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
YES1 | SNV | Missense_Mutation | rs763332220 | c.137N>T | p.Ser46Leu | p.S46L | P07947 | protein_coding | tolerated(0.07) | benign(0.027) | TCGA-A2-A04W-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
YES1 | SNV | Missense_Mutation | | c.760G>C | p.Val254Leu | p.V254L | P07947 | protein_coding | deleterious(0.04) | benign(0.02) | TCGA-BH-A0DG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
YES1 | insertion | In_Frame_Ins | novel | c.116_117insAGG | p.Val39_Ser40insGly | p.V39_S40insG | P07947 | protein_coding | | | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
YES1 | insertion | Nonsense_Mutation | novel | c.115_116insGCCATTCTAATAACTGTAAAGATAAACTCTAA | p.Val39GlyfsTer11 | p.V39Gfs*11 | P07947 | protein_coding | | | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
YES1 | insertion | Nonsense_Mutation | novel | c.57_58insGAGAGAAAATGAGCTCTTTTGTAAAGGGTCCCGTATCAGGATGCTT | p.Asn20GlufsTer4 | p.N20Efs*4 | P07947 | protein_coding | | | TCGA-BH-A0B4-01 | Breast | breast invasive carcinoma | Male | >=65 | III/IV | Hormone Therapy | tamoxiphen | SD |
YES1 | deletion | Frame_Shift_Del | novel | c.846delN | p.Lys282AsnfsTer2 | p.K282Nfs*2 | P07947 | protein_coding | | | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD |
YES1 | SNV | Missense_Mutation | | c.388N>A | p.Glu130Lys | p.E130K | P07947 | protein_coding | tolerated(0.35) | benign(0.062) | TCGA-DG-A2KM-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
YES1 | SNV | Missense_Mutation | | c.1034N>C | p.Tyr345Ser | p.Y345S | P07947 | protein_coding | deleterious(0) | probably_damaging(0.98) | TCGA-Q1-A5R1-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
YES1 | SNV | Missense_Mutation | rs202083013 | c.403G>A | p.Ala135Thr | p.A135T | P07947 | protein_coding | tolerated(1) | benign(0) | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
YES1 | SNV | Missense_Mutation | | c.1153N>A | p.Ala385Thr | p.A385T | P07947 | protein_coding | deleterious(0.02) | possibly_damaging(0.748) | TCGA-AA-3715-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
7525 | YES1 | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, ENZYME, CLINICALLY ACTIONABLE | | GSK-625137A | GSK-625137A | |
7525 | YES1 | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, ENZYME, CLINICALLY ACTIONABLE | | GW831090X | GW831090X | |
7525 | YES1 | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, ENZYME, CLINICALLY ACTIONABLE | | SB-221466 | CHEMBL95502 | |
7525 | YES1 | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, ENZYME, CLINICALLY ACTIONABLE | | GW827102X | GW827102X | |
7525 | YES1 | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, ENZYME, CLINICALLY ACTIONABLE | | SB-203580 | SB-203580 | |
7525 | YES1 | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, ENZYME, CLINICALLY ACTIONABLE | | GW631581B | GW631581B | |
7525 | YES1 | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, ENZYME, CLINICALLY ACTIONABLE | | CYC-116 | CYC-116 | |
7525 | YES1 | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, ENZYME, CLINICALLY ACTIONABLE | | GW837331X | GW837331X | |
7525 | YES1 | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, ENZYME, CLINICALLY ACTIONABLE | | SK&F-86002 | CHEMBL313417 | |
7525 | YES1 | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, ENZYME, CLINICALLY ACTIONABLE | | REGORAFENIB | REGORAFENIB | |